The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 101–200 of 857
The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury
Funke, M., Zhao, Z., Xu, Y., Chun, J., & Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0155oc · Cited by 141
Self-citationLPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis
Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272443 · Cited by 140
Insights into the pharmacological relevance of lysophospholipid receptors
Mutoh, T., Rivera, R., & Chun, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01622.x · Cited by 137
“, 2007) and lung (Tager et al., 2008), and male infertility (Ye et al.”
BackgroundSelf-citationAutotaxin in Pathophysiology and Pulmonary Fibrosis
Ninou, I., Magkrioti, C., & Aidinis, V. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00180 · Cited by 144
“Little is known on LPARs functional conformation and possible associations; LPAR1 has been detected in lipid rafts (73, 74) and suggested to heterodimerize with CD14 (74) and CD97 (75).”
BackgroundResultInfluentialAutotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation
Park, G. Y., Lee, Y. G., Berdyshev, E. V., Nyenhuis, S. M., Du, J., Fu, P., Gorshkova, I. A., Li, Y., Chung, S., Karpurapu, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1014oc · Cited by 135
“LPA levels were increased in the airways of patients with idiopathic pulmonary fibrosis and in BAL fluids after bleomycininduced lung injury of mouse model, and mice lacking the LPA1 receptor were markedly protected from fibrosis and mortality (16).”
Self-citationFibroblasts and the Ground They Walk On
Tschumperlin, D. J. (2013) · Physiology · doi:10.1152/physiol.00024.2013 · Cited by 123
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 141
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 150
“Myofibroblast-specific targeting of Rho–ROCK signalling is possible at the level of upstream G protein-coupled receptors (GPCRs) and their ligands, such as the lysophosphatidic acid (LPA) receptor 111,112 , the dopamine D 1 receptor 113 and the oestrogen GPCR 114 .”
Biological roles of lysophospholipid receptors revealed by genetic null mice: An update
Choi, J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.03.004 · Cited by 132
“In addition, the accumulation of fibroblasts was dramatically reduced in the injured lungs of LPA1-null mice, and the persistent vascular leak produced by bleomycin-induced injury was notably attenuated in LPA1-null mice [50].”
BackgroundInfluentialIdiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches
Glass, D. S., Grossfeld, D. J., Renna, H. A., Agarwala, P., Spiegler, P. A., Kasselman, L. J., Glass, A. D., DeLeon, J. R., & Reiss, A. B. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.04.002 · Cited by 138
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
Swaney, J. S., Chapman, C. W., Correa, L. D., Stebbins, K. J., Broadhead, A. R., Bain, G., Santini, A. M., Darlington, J. V., King, C. D., Baccei, C. S., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175901 · Cited by 146
Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis
Ohta, H., Chiba, S., Ebina, M., Furuse, M., & Nukiwa, T. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00349.2010 · Cited by 130
“The molecular mechanism of the regulation of alveolar flooding and fibrosis remains unclear, but disruption of the alveolar permeability barrier is considered to be an important step (6, 46).”
BackgroundAutotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions
Benesch, M. G. K., Ko, Y. M., McMullen, T. P. W., & Brindley, D. N. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.009 · Cited by 135
“Abbreviations: ATX, autotaxin; BALF, bronchoalveolar lavage fluid; C18:0 etc., indicates the numbers of carbon atoms in a fatty acid and the number of double bonds; COX-2, cyclooxygenase-2; ENPP2, ecto-nucleotide pyrophosphatase/phosphodiesterase family member 2; EGF, epidermal growth factor; HCC, hepatocellular carci…”
BackgroundInfluentialKnipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P., Zhang, L., Black, K. E., Sakai, N., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0075oc · Cited by 117
Self-citationMolecular imaging of fibrosis: recent advances and future directions
Montesi, S. B., Désogère, P., Fuchs, B. C., & Caravan, P. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122132 · Cited by 127
Tokumura, A., Carbone, L. D., Yoshioka, Y., Morishige, J., Kikuchi, M., Postlethwaite, A. E., & Watsky, M. A. (2009) · International Journal of Medical Sciences · doi:10.7150/ijms.6.168 · Cited by 135
“In a second recent study linking LPA to a fibrotic pathology, LPA was found to be elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis, and inhibition of the LPA1 receptor reduced the chemotactic activity of this fluid towards fibroblasts (36).”
BackgroundGlycerol-3-phosphate is an FGF23 regulator derived from the injured kidney
Šimić, P., Kim, W., Zhou, W., Pierce, K. A., Chang, W., Sykes, D. B., Aziz, N., Elmariah, S., Ngo, D., Pajevic, P. D., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131190 · Cited by 135
“Lpar1–/+ mice were generated in-house (52, 53); because of low fertility, these mice were backcrossed for 5 generations with CD-1 mice before in-house generation of Lpar1–/– mice.”
MethodSelf-citationStructural insights into ligand recognition by the lysophosphatidic acid receptor LPA6
Taniguchi, R., Inoue, A., Sayama, M., Uwamizu, A., Yamashita, K., Hirata, K., Yoshida, M., Tanaka, Y., KATO, H. E., Nakada-Nakura, Y., et al. (2017) · Nature · doi:10.1038/nature23448 · Cited by 129
Huang, L. S., Sudhadevi, T., Fu, P., Kannan, P. K. P., Ebenezer, D. L., Ramchandran, R., Putherickal, V., Cheresh, P., Zhou, G., Ha, A. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062064 · Cited by 128
Barbayianni, E., Kaffe, E., Aidinis, V., & Kokotos, G. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.02.001 · Cited by 129
Fu, C., Hao, S., Xu, X., Zhou, J., Liu, Z., Lu, H., Wang, L., Jin, W., & Li, S. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0045-3 · Cited by 126
Mirzaei, S., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Azami, N., Hamzehlou, S., Farahani, M. V., Hushmandi, K., Ashrafizadeh, M., et al. (2021) · Antioxidants · doi:10.3390/antiox10030349 · Cited by 134
Role of integrin-mediated TGFβ activation in the pathogenesis of pulmonary fibrosis
Goodwin, A. T., & Jenkins, G. R. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370849 · Cited by 140
Tissue remodelling in pulmonary fibrosis
Knudsen, L., Ruppert, C., & Ochs, M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2543-2 · Cited by 129
“In IPF patients, the levels of LPA are increased in the bronchoalveolar lavage and LPA 1 -receptor knockout mice are protected from bleomycin-induced fibrosis providing evidence that this pathway is also involved in human IPF (Tager et al. 2008).”
BackgroundTargeting the vascular and perivascular niches as a regenerative therapy for lung and liver fibrosis
Cao, Z., Ye, T., Sun, Y., Ji, G., Shido, K., Chen, Y., Luo, L., Na, F., Li, X., Huang, Z., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8710 · Cited by 117
Vascular involvement in systemic sclerosis (scleroderma)
Postlethwaite, Pattanaik, D., & Brown, M. (2011) · Journal of Inflammation Research · doi:10.2147/jir.s18145 · Cited by 119
“144–148 S1P has been shown to regulate fibrosis in animal models of eye and cardiac fibrosis.”
Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling
Zhao, Y., & Natarajan, V. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.014 · Cited by 124
“LPA levels in bronchoalveolar lavage (BAL) increase in lung inflammatory diseases, such as asthma [27, 28], fibrosis [29], and acute lung injury [16].”
BackgroundInfluentialTissue-resident mesenchymal stromal cells: Implications for tissue-specific antifibrotic therapies
Lemos, D. R., & Duffield, J. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5174 · Cited by 113
“Lysophosphatidic acid (LPA) receptor 1 (LPAR1), a G protein– coupled receptor restricted to fibroprogenitor cells and their progeny, has become an attractive target for fibrosis (64).”
BackgroundHussey, G. S., Pineda Molina, C., Cramer, M. C., Tyurina, Y. Y., Tyurin, V. A., Lee, Y. C., El-Mossier, S. O., Murdock, M. H., Timashev, P. S., Kagan, V. E., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4361 · Cited by 108
“LPL profiles of liquid-phase EV, MBV, and parent cells LPLs, hydrolytic metabolites of phospholipids created by phospholipases A, are bioactive signaling molecules that modulate a variety of physiological responses, including macrophage activation (23), inflammation and fibrosis (24), tissue repair and remodeling (25)…”
BackgroundAutotaxin and chronic inflammatory diseases
Magkrioti, C., Galaris, A., Kanellopoulou, P., Stylianaki, E.-A., Kaffe, E., & Aidinis, V. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102327 · Cited by 116
Roles of lysophosphatidic acid in cardiovascular physiology and disease
Smyth, S. S. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.05.008 · Cited by 112
Fibrosis in Systemic Sclerosis
Varga, J., & Trojanowska, M. (2008) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.11.002 · Cited by 119
Parimon, T., Yao, C., Habiel, D. M., Ge, L., Bora, S. A., Brauer, R., Evans, C. M., Xie, T., Alonso-Valenteen, F., Medina-Kauwe, L. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129359 · Cited by 104
“To further complicate things, lipids, which are EV constituents, can also mediate lung fibrosis (79).”
BackgroundWang, J., Sun, Y., Teng, S., & Li, K. (2020) · BMC Medicine · doi:10.1186/s12916-020-01546-5 · Cited by 118
Lysophosphatidic acid and renal fibrosis
Pradère, J., Gonzalez, J., Klein, J., Valet, P., Grès, S., Salant, D. J., Bascands, J., Saulnier‐Blache, J. S., & Schanstra, J. P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.04.001 · Cited by 116
CXCL10 Can Inhibit Endothelial Cell Proliferation Independently of CXCR3
Campanella, G. S. V., Colvin, R. A., & Luster, A. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012700 · Cited by 108
“Isolation of primary heart endothelial cells Heart endothelial cells were isolated from wildtype or CXCR3 KO C57Bl/6 mice as previously described [46,47], with slight modifications.”
Self-citationHuang, L. S., Fu, P., Patel, P., Harijith, A., Sun, T., Zhao, Y., Garcia, J. G. N., Chun, J., & Natarajan, V. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0070oc · Cited by 104
“In the bleomycin-induced pulmonary fibrosis model, LPA1 deficiency conferred significant protection against bleomycin-induced fibrosis and mortality (16, 20).”
BackgroundResultInfluentialSelf-citationAn Autotaxin/Lysophosphatidic Acid/Interleukin‐6 Amplification Loop Drives Scleroderma Fibrosis
Castelino, F. V., Bain, G., Pace, V. A., Black, K. E., George, L., Probst, C. K., Goulet, L., Lafyatis, R., & Tager, A. M. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39797 · Cited by 108
“and eosin (H&E) or Masson’s trichrome according to the standard protocols of our laboratory (21).”
BackgroundSelf-citationAberrant Pulmonary Vascular Growth and Remodeling in Bronchopulmonary Dysplasia
Alvira, C. M. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00021 · Cited by 105
Autophagy markers as mediators of lung injury-implication for therapeutic intervention
Vishnupriya, S., Dharshini, L. C. P., Sakthivel, K. M., & Rasmi, R. R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118308 · Cited by 112
Liu, S., Paknejad, N., Zhu, L., Kihara, Y., Ray, M., Chun, J., Liu, W., Hite, R. K., & Huang, X.-Y. (2022) · Nature Communications · doi:10.1038/s41467-022-28417-2 · Cited by 96
“A HA signal peptide and a Flag tag were fused to the human LPA1 (2-340) or human S1P1 (2-347), followed by the PreScission protease cleavage site, eGFP and 8xHis tag at the C-terminus.”
MethodSelf-citationMaher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Trujillo, G., O'Connor, E. C., Kunkel, S. L., & Hogaboam, C. M. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070832 · Cited by 100
Lysophosphatidic acid converts monocytes into macrophages in both mice and humans
Ray, R., & Rai, V. (2017) · Blood · doi:10.1182/blood-2016-10-743757 · Cited by 101
“The Journal of experimental medicine 2005; 201(10): 1615-25.”
BackgroundInfluentialStructure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin
Albers, H. M. H. G., Hendrickx, L. J. D., van Tol, R. J. P., Hausmann, J., Anastassis Perrakis, A., & Ovaa, H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200310q · Cited by 98
Matrix biomechanics and dynamics in pulmonary fibrosis
Haak, A. J., Tan, Q., & Tschumperlin, D. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.004 · Cited by 95
“Vascular leak contributes to both lung injury and pulmonary fibrosis (103), and high stretch levels can activate TGF-beta from the lung ECM (104).”
BackgroundVenkatraman, G., Benesch, M. G. K., Tang, X., Dewald, J. W., McMullen, T. P. W., & Brindley, D. N. (2014) · The FASEB Journal · doi:10.1096/fj.14-262659 · Cited by 96
“These processes become dysfunctional in chronic inflammatory conditions, such as arthritis (10, 11), pulmonary fibrosis (12), and inflammatory bowel disease (13), which are accompanied by tissue destruction and fibrosis.”
BackgroundTargeting sphingosine kinase 1 attenuates bleomycin‐induced pulmonary fibrosis
Huang, L. S., Berdyshev, E. V., Mathew, B., Fu, P., Gorshkova, I. A., He, D., Ma, W., Noth, I., Ma, S., Pendyala, S., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-219634 · Cited by 98
The cytokines of pulmonary fibrosis: Much learned, much more to learn
Luzina, I. G., Todd, N. W., Sundararajan, S., & Atamas, S. P. (2014) · Cytokine · doi:10.1016/j.cyto.2014.11.008 · Cited by 100
Yukiura, H., Hama, K., Nakanaga, K., Tanaka, M., Asaoka, Y., Okudaira, S., Arima, N., Inoue, A., Hashimoto, T., Arai, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.301093 · Cited by 91
Shea, B. S., & Tager, A. M. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-005aw · Cited by 92
“Consistent with this hypothesis, LPA1 KO mice exhibited decreased intraalveolar coagulation in addition to decreased vascular leak after bleomycin lung injury (14).”
BackgroundInfluentialSelf-citationLovgren, A. K., Kovacs, J. J., Xie, T., Potts, E. N., Li, Y., Foster, W. M., Liang, J., Meltzer, E. B., Jiang, D., Lefkowitz, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001564 · Cited by 89
“Loss of b-arrestins could potentially alter receptor internalization and thus cell surface expression of LPA1 or other receptors important in fibroblast chemotaxis.”
InfluentialRindlisbacher, B., Schmid, C., Geiser, T., Bovet, C., & Funke-Chambour, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0714-2 · Cited by 93
“Previous studies showed increased level of LPA in the bronchoalveolar lavage fluid and exhaled breath condensate of IPF patients [42, 54].”
BackgroundNovel mechanisms regulating endothelial barrier function in the pulmonary microcirculation
Simmons, S., Erfinanda, L., Bartz, C., & Kuebler, W. M. (2018) · The Journal of Physiology · doi:10.1113/jp276245 · Cited by 91
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 90
Lee, S.-C., Fujiwara, Y., Liu, J., Yue, J., Shimizu, Y., Norman, D. D., Wang, Y., Tsukahara, R., Szabó, E., Patil, R., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0263 · Cited by 88
“A more recent study by Tager and colleagues described the involvement of LPA1 receptors in increasing vascular leakage following tissue injury in a bleomycin mouse model of pulmonary fibrosis (47).”
BackgroundDenervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β
Rebolledo, D. L., González, D., Faundez-Contreras, J., Contreras, O., Vio, C. P., Murphy-Ullrich, J. E., Lipson, K. E., & Brandan, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.01.002 · Cited by 97
Matrix-driven Myosin II Mediates the Pro-fibrotic Fibroblast Phenotype
Southern, B. D., Grove, L. M., Rahaman, S. O., Abraham, S., Scheraga, R. G., Niese, K. A., Sun, H., Herzog, E. L., Liu, F., Tschumperlin, D. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.712380 · Cited by 85
Lysophosphatidic acid-1-receptor targeting agents for fibrosis
Rancoule, C., Pradère, J., Gonzalez, J., Klein, J., Valet, P., Bascands, J., Schanstra, J. P., & Saulnier‐Blache, J. S. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.566864 · Cited by 93
“Furthermore, bronchoalveolar lavage fluid obtained from idiopathic pulmonary fibrosis patients induced chemotaxis of human foetal lung fibroblasts that was blocked by the LPA1R antagonist Ki16425 [59].”
BackgroundMatas-Rico, E., Frijlink, E., Àvila, I. V. D. H., Menegakis, A., van Zon, M., Morris, A. J., Köster, J., Salgado-Polo, F., de Kivit, S., Lança, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110013 · Cited by 91
“LPAR1 also mediates the recruitment and activation of fibroblasts, a prototypic ATX-secreting cell type, and the ATX-LPAR axis is implicated in promoting tissue fibrosis (Ledein et al., 2020; Sakai et al., 2019; Tager et al., 2008).”
Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis
Miyabe, Y., Miyabe, C., Iwai, Y., Takayasu, A., Fukuda, S., Yokoyama, W., Nagai, J., Jona, M., Tokuhara, Y., Ohkawa, R., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37991 · Cited by 85
Self-citationTsou, P., Haak, A. J., Khanna, D., & Neubig, R. R. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00060.2014 · Cited by 96
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Castagna, D., Budd, D. C., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01599 · Cited by 88
Tang, N., Zhao, Y., Feng, R., Liu, Y., Wang, S., Wei, W., Ding, Q., An, M. (., Wen, J., & Li, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12178 · Cited by 87
“As LPA-LPA1 signalling, together with TGF-b1, plays an important role in the accumulation of myofibroblasts [3, 4, 43, 44], we measured both LPA and TGF-b1 levels in the lungs of mice treated with BLM.”
BackgroundInfluentialCurrent progress in non-Edg family LPA receptor research
Yanagida, K., Kurikawa, Y., Shimizu, T., & Ishii, S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.08.003 · Cited by 82
“can be detected in other body fluids as well such as saliva [3], seminal plasma [4], and bronchoalveolar lavage fluid [5].”
BackgroundDong, W., Liu, Y., Zhou, L., Mao, Y., Wang, Y., Zhu, X., & Jiang, L. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.004 · Cited by 84
“modified from a previously published technique [27].”
Sakai, N., Chun, J., Duffield, J. S., Lagares, D., Wada, T., Luster, A. D., & Tager, A. M. (2017) · Kidney International · doi:10.1016/j.kint.2016.09.030 · Cited by 80
Self-citationSakai, N., Nakamura, M., Lipson, K. E., Miyake, T., Kamikawa, Y., Sagara, A., Shinozaki, Y., Kitajima, S., Toyama, T., Hara, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05624-2 · Cited by 83
Self-citationSphingolipids in pulmonary fibrosis
Huang, L. S., & Natarajan, V. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.008 · Cited by 80
“Bronchoalveolar lavage (BAL) fluid from IPF patients showed enhanced LPA (Tager et al., 2008) and S1P (Milara et al., 2012) levels compared to control subjects.”
BackgroundVázquez‐Medina, J. P., Dodia, C., Weng, L., Mesaros, C., Blair, I. A., Feinstein, S. I., Chatterjee, S., & Fisher, A. B. (2016) · The FASEB Journal · doi:10.1096/fj.201500146r · Cited by 80
“However, more studies are needed to confirm the role of LPAR1 and also to demonstrate the particular LPARs that are involved in NOX2 activation in AMs, which express LPAR-2, -4, and -5 (64), as well as in other cell types that generate O2 •2 viaNOX2 activation.”
BackgroundInfluentialMa, H., Wu, X., Li, Y., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963054 · Cited by 86
“ATX is the key enzyme for LPA synthesis Tager et al. (2008); Ninou et al. (2018); Suryadevara et al. (2020) SPHK1-S1P-S1PR The binding of S1P-to-S1PR can lead tomitochondrial reactive oxygen species (mtROS) and promote YAP1 to enter cell nuclei, affecting the differentiation of myofibroblasts and…”
BackgroundNon-Edg family lysophosphatidic acid (LPA) receptors
Ishii, S., Noguchi, K., & Yanagida, K. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.06.001 · Cited by 91
Panchatcharam, M., Salous, A. K., Brandon, J. A., Miriyala, S., Wheeler, J., Patil, P., Sunkara, M., Morris, A. J., Escalante‐Alcalde, D., & Smyth, S. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302335 · Cited by 79
Molecular programs of fibrotic change in aging human lung
Lee, S., Islam, M. N., Boostanpour, K., Aran, D., Jin, G., Christenson, S., Matthay, M. A., Eckalbar, W. L., DePianto, D. J., Arron, J. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26603-2 · Cited by 78
Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy
Chen, R., & Dai, J. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02336-1 · Cited by 85
“Besides, LPA concentration in BAL fluids from IPF patients is significantly higher than in normal controls, and the LPA1 antagonist reduces fibroblast chemotaxis in IPF [83].”
BackgroundBlockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation
Gan, L., Xue, J., Li, X., De-song, L., Ge, Y., Ni, P., Deng, L., Lü, Y., & Jiang, W. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.084 · Cited by 78
“LPAR1 deficiency induces psychiatric diseases in rodents [22], but ameliorates neuropathic pain [23], higher adiposity [24] and fibrosis [11,13,15,17].”
BackgroundMethodInfluentialDiscovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin
Albers, H. M. H. G., van Meeteren, L. A., Egan, D. A., van Tilburg, E. W., Moolenaar, W. H., & Ovaa, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1005012 · Cited by 78
Lysophosphatidic acid signaling in airway epithelium: Role in airway inflammation and remodeling
Zhao, Y., & Natarajan, V. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.010 · Cited by 78
Non-Edg family LPA receptors: the cutting edge of LPA research
Yanagida, K., & Ishii, S. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr087 · Cited by 77
Sluis, G. L. V., Niers, T. M. H., Esmon, C. T., Tigchelaar, W., Richel, D. J., Buller, H. R., Noorden, C. J. F. V., & Spek, C. A. (2009) · Blood · doi:10.1182/blood-2009-04-217679 · Cited by 75
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
Kaffe, E., Magkrioti, C., & Aidinis, V. (2019) · Cancers · doi:10.3390/cancers11111626 · Cited by 73
“attenuated pulmonary fibrosis, vascular leak and inflammation, attributed to blocked LPA signaling or decreased LPA levels, respectively [64,70,71].”
BackgroundInfluentialNew Insights into the Pathophysiology of Sickle Cell Disease-Associated Priapism
Bivalacqua, T. J., Musicki, B., Kutlu, Ö., & Burnett, A. L. “. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02288.x · Cited by 76
Ding, B., Liu, C. H., Sun, Y., Chen, Y., Swendeman, S. L., Jung, B., Chavez, D., Cao, Z., Christoffersen, C., Nielsen, L. B., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87058 · Cited by 75
Ma, L., Uchida, H., Nagai, J., Inoue, M., Aoki, J., & Ueda, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164830 · Cited by 73
Structural basis for specific inhibition of Autotaxin by a DNA aptamer
Kato, K., Ikeda, H., Miyakawa, S., Futakawa, S., Nonaka, Y., Fujiwara, M., Okudaira, S., Kano, K., Aoki, J., Morita, J., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3200 · Cited by 71
Chemical Evolution of Autotaxin Inhibitors
Albers, H. M. H. G., & Ovaa, H. (2012) · Chemical Reviews · doi:10.1021/cr2003213 · Cited by 76
Zhao, J., He, D., Su, Y., Berdyshev, E. V., Chun, J. J. M., Natarajan, V., & Zhao, Y. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00058.2011 · Cited by 71
“The proinflammatory effects of LPA receptors in lung inflammatory diseases have been demonstrated (1, 38, 47).”
BackgroundInfluentialSelf-citationCorte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0977oc · Cited by 70
Benesch, M. G. K., MacIntyre, I., McMullen, T. P. W., & Brindley, D. N. (2018) · Cancers · doi:10.3390/cancers10030073 · Cited by 74
“Mice that lacked LPA1 were more resistant to fibrosis via bleomycin challenge [111,112].”
BackgroundTargeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
Haak, A. J., Ducharme, M. T., Diaz Espinosa, A. M., & Tschumperlin, D. J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.008 · Cited by 65
“For example, LPA has been shown to be increased in the bronchial alveolar lavage fluid (BALF) [29], and exhaled breath condensate (EBC) [25] from patients with idiopathic pulmonary fibrosis, and in rodent models of pulmonary fibrosis [26–28].”
BackgroundWatsky, M. A., Weber, K. T., Sun, Y., & Postlethwaite, A. E. (2010) · International review of cytology · doi:10.1016/s1937-6448(10)82004-0 · Cited by 71
Ikeda, H., & Yatomi, Y. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.07.014 · Cited by 75
Zhao, Y., Tong, J., He, D., Pendyala, S., Evgeny, B., Chun, J. J. M., Sperling, A. I., & Natarajan, V. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-114 · Cited by 68
“Deletion of LPA1 reduced fibroblast recruitment and vascular leak in the bleomycin model of pulmonary fibrosis [29] while LPA/LPA2 signaling via αvβ6 integrin-mediated activation of TGF-β has been implicated in the development of bleomycin-induced lung fibrosis in mice [54].”
BackgroundInfluentialSelf-citationAcid Sphingomyelinase Deficiency Attenuates Bleomycin-Induced Lung Inflammation and Fibrosis in Mice
Dhami, R., He, X., & Schuchman, E. H. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000322342 · Cited by 68
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
Sun, M., Sun, Y., Feng, Z., Kang, X., Yang, W., Wang, Y., & Luo, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105635 · Cited by 72
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Montesi, S. B., Mathai, S. K., Brenner, L. N., Gorshkova, I. A., Berdyshev, E. V., Tager, A. M., & Shea, B. S. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-5 · Cited by 66
“This study builds on previous work showing that LPA is increased in BAL fluid in IPF patients [13], and advances the current field of pulmonary research by showing that LPA can be extracted from EBC.”
BackgroundResultSelf-citationAutocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis
Cao, P., Aoki, Y., Badri, L., Walker, N., Manning, C. M., Lagstein, A., Fearon, E. R., & Lama, V. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88896 · Cited by 66
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
“Increased LPA levels have also been seen in the BALF from patients with IPF [130].”
BackgroundLysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox
Llona‐Minguez, S., Ghassemian, A., & Helleday, T. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.01.004 · Cited by 66
“In addition to the strong implications in cancer pathology, LPA1 plays an important role in lung and kidney fibrosis [37,38], and small-molecule LPA1 antagonists have shown anti-fibrotic activity in rodent models [39–41].”
Background
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.